Repligen Co. (NASDAQ:RGEN) Stock Position Boosted by Treasurer of the State of North Carolina

Treasurer of the State of North Carolina grew its stake in shares of Repligen Co. (NASDAQ:RGEN) by 0.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 24,500 shares of the biotechnology company’s stock after buying an additional 160 shares during the quarter. Treasurer of the State of North Carolina’s holdings in Repligen were worth $3,527,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently made changes to their positions in the company. Signaturefd LLC raised its holdings in Repligen by 172.2% during the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 124 shares in the last quarter. Sava Infond d.o.o. bought a new stake in shares of Repligen in the 4th quarter worth $29,000. UMB Bank n.a. boosted its stake in Repligen by 49.1% during the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 110 shares in the last quarter. Global Retirement Partners LLC grew its holdings in Repligen by 54.0% during the fourth quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company’s stock worth $53,000 after acquiring an additional 129 shares during the period. Finally, Pilgrim Partners Asia Pte Ltd bought a new stake in Repligen in the fourth quarter worth about $55,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Repligen Trading Down 0.5 %

NASDAQ RGEN opened at $126.62 on Wednesday. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. Repligen Co. has a 1-year low of $102.97 and a 1-year high of $182.52. The firm’s fifty day simple moving average is $141.72 and its 200-day simple moving average is $146.05. The company has a market capitalization of $7.11 billion, a PE ratio of -248.27, a price-to-earnings-growth ratio of 4.54 and a beta of 1.27.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.03. The company had revenue of $167.55 million during the quarter, compared to the consensus estimate of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. As a group, sell-side analysts anticipate that Repligen Co. will post 1.72 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Margaret Pax purchased 250 shares of Repligen stock in a transaction on Monday, March 17th. The stock was bought at an average price of $150.69 per share, with a total value of $37,672.50. Following the completion of the transaction, the director now directly owns 1,043 shares of the company’s stock, valued at approximately $157,169.67. This represents a 31.53 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.20% of the company’s stock.

Analyst Ratings Changes

RGEN has been the topic of several recent research reports. Royal Bank of Canada lifted their price objective on shares of Repligen from $203.00 to $205.00 and gave the stock an “outperform” rating in a research note on Friday, February 21st. HC Wainwright reiterated a “buy” rating and issued a $180.00 price target on shares of Repligen in a research report on Friday, February 21st. Canaccord Genuity Group boosted their price objective on Repligen from $165.00 to $170.00 and gave the stock a “hold” rating in a report on Friday, February 21st. Evercore ISI assumed coverage on shares of Repligen in a research report on Tuesday, March 18th. They issued an “in-line” rating and a $155.00 target price on the stock. Finally, Canaccord Genuity Group began coverage on shares of Repligen in a research report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target for the company. Seven research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $178.64.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.